This article is more than 5 years old. Information may no longer be current.

MacuLogix raises $3.6 million to advance tool for early AMD detection

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MacuLogix has secured $3.6 million in Series A funding to help speed manufacturing and commercial sales of its AdaptDx diagnostic tool, according to a company news release.

AdaptDx, designed for early detection and tracking of age-related macular degeneration, offers physicians a functional diagnostic tool similar to routine perimetry testing for glaucoma, the release said. Early detection will allow for the earliest possible intervention.

“We have completed numerous clinical studies involving more than 1,000 patients with additional studies ongoing, all at major research centers such as Harvard University, the National Eye Institute and University of Alabama at Birmingham. This financing allows us to take the next step,” John G. Edwards, CEO of MacuLogix, said in the release.

The funding comes from Berwind Private Equity, Roche Venture Fund, Life Sciences Greenhouse of Central Pennsylvania and Ben Franklin Technology Partners of Central and Northern Pennsylvania.